+34 679 490 537info@nanbiosis.com

CIBER

CIBER

You are here : Home / CIBER

Smart-4-Fabry final workshop

Next Wedneday, February 3, 2021 will take place the on-line event Smart-4-Fabry Final Workshop.  

Smart-4-Fabry is a european project, coordinated by CIBER-BBN wich has been developed during four years. This project is a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages.

This project is also a clear example of the relevance of access to advanced research infrastructures as NANBIOSIS -ICTS. Four NANBIOSIS units have collaborated and contributed to Smart-4-Fabry development:

“The Fabry disease (FD) is a lysosomal storage disorder (LSD) that currently lacks an effective treatment” as Prof. Nora Ventosa, IP of the project, explained for NANBIOSIS blog – The aim of Smart-4-Fabry is to obtain a new nanoformulation of GLA, that will improve the efficacy and toleration compared to the actual treatment with non-formulated GLA.

In the final workshop experts will talk about how, why and for what the solution proposed by Smart4Fabry was conceived.

Registrations and program at https://smart4fabry.cientifis.com/

• Read More

NANBIOSIS in the new poster of ICTS map published by Spanish Goverment.

ICTS underpins the Spanish reputation for research excellence.

In the picture: the new poster of the ICTS map in which NANBIOSIS facilities have been highlighed with a red square

The term Unique Scientific and Technical Infrastructure (ICTS) refers to facilities, resources, or services for the development of top-quality cutting-edge research, as well as the communication, exchange, and preservation of knowledge, the transfer of technology, and promotion of innovation. They are unique or exceptional in their fields, with a high cost of investment, maintenance, and operation, and are of a strategic importance that justifies their availability to all actors in the field of R&D&I. The ICTS share three fundamental characteristics; they are infrastructures with public ownership, unique and open to competitive access.

ICTS offer an opening capacity percentage of their essential services under ‘Competitive Open Access’ for the use by national and international public and private sector researchers, with the support of technical and administrative personnel of the ICTS. Infrastructures access is ruled by a public “Access Protocol” that describes the procedure and criteria for access to the infrastructure. The main features of ‘Competitive Open Access’ are that R + D + i quality of activities developed at the infrastructure should be proven and that requests for access should be prioritized on the basis of objective criteria.

The dissemination of ICTS and their capabilities is essential to provide Spanish and international researchers with access to a large base of quality services and facilities, a basic requirement for the development of excellent science.

The new posster pushised by the General Subdirectorate of Large
Scientific-Technical Facilities of the of the Sapanish Ministry of Science and Research Innovation helps to disseminate and understand the map of ICTS wich are located throughout the country

NANBIOSIS, is one of the five ICTS in the field of Health Sciences and Biotechnology

Further informations: MICINN

• Read More

Scientists of Bionand, University of Malaga and CIBER identify a new drug that could mitigate the consequences of COVID infection.

Researchers from Bionand, partner of NANBIOSIS and ​​the University of Malaga toguether with Red de Terapia Celular, CIBER-BBN and CIBER-NED have taken another step in the search for new rapidly implantable therapies to stop the pandemic caused by the coronavirus disease, identifying a new drug that could prevent or mitigate the consequences of the SARS-CoV-2 infection.

The team, led by UMA researchers Iván Durán and Fabiana Csukasi, will study over the next year how treatment with 4-Phenylbutyrate (4-PBA) modulates the inflammatory response that occurs in the most severe cases of COVID-19.

The first results have already been published in the scientific journal ‘Cytokine and Growth Factors Review’

The inflammatory process that is identified in the most serious cases of coronavirus causes uncontrolled and excess cytokines – molecules responsible for organizing the body’s defenses – even triggering vascular hyperpermeability and multi-organ failure. Precisely, the control of this “storm” of cytokines, through those who control them, that is, the infected cells, is the proposal of the researchers from the University of Malaga.

“When cells are stressed by the infection they call up the cytokines and, the more stressed they are, the more insistently they call them, causing that uncontrolled inflammation. For this reason, one possibility to treat COVID-19 is to reduce the stress on the cells, “explained Durán.

According to the researcher, repositioning with the anti-stress drug ‘4-PBA’, approved for clinical use against other diseases and, therefore, easy to take to the clinic, could modulate this cellular stress, which is also present in pathologies such as diabetes, aging or carcinogenesis, in turn, classified as risk for Covid-19.

For further information click here

Other members of the Bioengineering and Tissue Regeneration Laboratory (Labret), led by Professor José Becerra, and of which the researchers Manuel Mari-Beffa, Gustavo Rico, José Miguel Tejeiro, Rick Visser and David Baglietto are also part of the team of researchers in this project granted by de Andalucía Government with 90.000€.

• Read More

NANBIOSIS AT THE CIBER-BBN ANNUAL CONFERENCE 2019

On October 21 and 22, CIBER-BBN has celebrated its 13th Annual Conference  in Tarragona, with a session dedicated to NANBIOSIS on the afternoon of Monday 21. The Singular Technical Scientific Infrastructure (ICTS) for the production and characterization of biomaterials, nanomaterials and devices up to its preclinical validation for the production and characterization of biomaterials, nanomaterials and devices up to its preclinical validation is integrated by of the CIBER-BBN, the Minimally Invasive Surgery Center Jesus Usón and Bionand after its incorporation to the ICTS last year. NANBIOSIS, presented its annual activity.

The Session was chaired by its Scientific Director, Jaume Veciana who also gave an Annual Summary, after that, the new unit 29 of NANBIOSIS, the Oligonucleotide Synthesis Platform, was presented by its Scientific Director Ramon Eritja Casadellà, from CIBER-BBN and Catalan Institute of Advanced Chemistry- CSIC . Finally, the Infrastructure for OMICS technologies (OmicsTech ICTS): metabolomics for clinical and nutritional research, was presented by Xavier Domingo-Almenara, Centre for Omics Sciences, EURECAT- Rovira i Virgili University.

After the NANBIOSIS Session, was the NANBIOSIS Scientificic Advisory Board meeting.

• Read More

CIBER-BBN Annual Conference 2019

In one month CIBER-BBN will celebrate its 13th Annual Conference on October 20 and 21 in Tarragona, at the Hotel Ciutat de Tarragona, Tarragona.

This year there several scientific sessions are planned about related leading issues with research topics of interest to CIBER-BBN. On Monday there will be three sessions centered in:

  • artificial intelligence and big data
  • gene editing and CRISPR and
  • liquid biopsy and point-ofcare.

Each of these sessions will include a plenary conference given by an expert
guest and two talks by BBN researchers, followed by an open debate.

The program will complete a session focused on the Singular Technical Scientific Infrastructure NANBIOSIS-ICTS.

On Tuesday, the four prizes will be awarded to the best scientific articles published by young researchers of CIBER-BBN during 2018 and there will be two other sessions on

  • nanobots and emerging drug administration technologies and
  • senescence and reprogramming

• Read More

Safe-N-Medtech kicks off in Bilbao

The Safe-N-MedTech European Project kcks off in Bibao to create an open innovation platform that accelerates the development of medical devices based on nanotechnologies.

During 2 and 3 of May took place in Bilbao, at the University of the Basque Country, the kick off meeting of the European project Safe-N-Medtech organized by Osteba, the HTA Unit of the Ministry of Health of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY.

Safe-N-Medtech, counts with 28 partnerts coordinated by TECNAN (Navarran company with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY, the research branch of the global health companies Keralty and Praxis. The new project is part of the Open Innovation Test Bed initiative (OITB) launched by the European Commission with the aim of accelerating the development of medical devices based on nanotechnologies in Europe and abroad. The project has a European funding of 15 million euros.

CIBER-BBN participates as a partner in the Safe-N-Medtech throught its Scientific Infraestructure, the ICTS NANBIOSIS. Several units of NANBIOSIS from CIBER-BBN and JUMISC wiil carry out some of the F/Q, in vivo and in vitro characterizations applied to pilot test cases, NANBIOSIS is the leader of WP3 Preclinical Research in nano-enabled MTs.

Society and clinical practice raise a growing demand for new biomaterials, ICTs, medical devices and in vitro diagnostics (Medical Technologies-MTs) based on micro and nanotechnologies. In addition to the challenge of time, new technologies are subject to other pressing factors, such as qualification, regulation, cost, biocompatibility and the need to be applicable throughout the world. Medical devices based on nanotechnologies can be applied in almost all medical areas, with an important presence in areas such as cancer, regenerative medicine, advanced therapies, neurology, cardiology, orthopedics and dentistry.

The initiative aims to build an open innovation platform to offer companies and reference laboratories the capabilities, knowledge, networks and services necessary for the development, testing, evaluation, improvement and exploitation of the market of medical devices and diagnostic based in nanotechnology. This platform will offer a multidisciplinary and market-oriented innovation approach for SMEs, health care providers and industries, accelerating the transfer to the market of these new medical devices. During the first years of project work, the partners will develop their services and test them in different case studies, so that, Safe-N-Medtech OITB can become a sustainable and competitive services platform for companies to accelerate their developments according to the necessary regulatory requirements and ensure the safety and effectiveness of their medical devices based on nanotechnologies.

• Read More

NANBIOSIS at CIBEREHD XI Annual Conferences

Jesús Izco, Coordinator of NANBIOSIS, has presented NANBIOSIS-ICTS at the XI annual Conference of  CIBEREHD, which takes place from 27 to 28 November 2017 at the Hotel Barceló Sants in Barcelona.

Jesús Izco has explained the opportunities offered by the ICTS NANBIOSIS as a Platform for Research and Biomedical Innovation, giving examples of private-public collaboration in competitive calls  in which NANBIOSIS has participated and explaining the design of the new Nanomedicine Cascade Characterization Service, in which NANBIOSIS is working on.

CIBEREHD (Center for biomedical research in liver and digestive diseases) is

The CIBER’s thematic area of Liver and Digestive Diseases (CIBEREHD) has the purpose of promoting and protecting health by furthering research. This work, whose scope includes both basic research and clinical and translational aspects, is based on the field of Liver and Digestive Diseases with the aim of innovating in the prevention of these diseases and promoting scientific and healthcare progress. At present the CIBEREHD is working on four corporate programmes:

P1. Mechanisms of liver damage/evolution into advanced cirrhosis and transplant.

P2. Gastrointestinal physiopathology: inflammatory illness and motility disorders.

P3. Epidemiology, prevention and treatment of viral hepatitis infection.

P4. Liver and Digestive Oncology

 

• Read More

NANBIOSIS in CIBER-BBN ANNUAL CONFERENCE 2017

CIBER-BBN will celebrate its 11th Annual Conference on November 13 and 14 in Santander. In these conference there will be a session dedicated to NANBIOSIS. Likewise, the annual meeting of the Scientific Technical Advisory Committee of NANBIOSIS will take place.

As in previous occasions, the meeting will serve to know the activity of NANBIOSIS, the Singular Technical Scientific Infrastructure (ICTS) of the CIBER-BBN and the Minimally Invasive Surgery Center Jesus Usón for the production and characterization of biomaterials, nanomaterials and devices up to its preclinical validation.

As a novelty, it will be presented at the conference, the new internal structure, generated by NANBIOSIS for the development of “turnkey” projects in which, taking advantage of the complementarity and experience of its Units, NANBIOSIS offers complete service packages, with added value, adapted to the client’s needs, for applications such as nanotherapeutic agents, regenerative medicine, medical and diagnostic devices, among others. Some of the packages that are already designed or in more advanced stages will be explained, among which stands out the service of characterization and cascade assessment of nanomaterials that includes the characterization of the physicochemical attributes, their biological properties in vitro (immunology, toxicology and efficacy), and its in vivo compatibility (immunology, toxicology and efficacy), using appropriate animal models, with the possibility of being subject to regulatory conditions of Good Laboratory Practices. Some success stories of these “turnkey” projects developed in NANBIOSIS will be shown.

On this occasion, in addition, it is planned a presentation of EATRIS , the European Infrastructure for the Translation of Medicine, with which NANBIOSIS has initiated a line of collaboration.

Since its launch in July 2015, NANBIOSIS has received more than 550 access requests through its website, with an average participation of some 80 competitive projects per year and with an annual income for its services of between 2 and 3 million euros. Among its users, there are more than 100 companies.

• Read More

NANBIOSIS presented at the 12th annual event of the ETPN

During the days 17-19 of October Malaga has hosted the 12th annual event of European Platform of Technology in Nanomedicine (ETPN), a European meeting of 200 experts in research and innovation in nanomedicine.

The meeting was organized by Bionand, the Spanish Platform of Nanomedicine (Nanomed Spain), the Institute of Nanoscience of Madrid (Imdea) and the Center for Biomedical Research Network in the area of ​​Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), partner of NANBIOSIS.

During the event, the ETPN General Assembly took place as well as parallel meetings of the specialized working groups on different scientific and cross-cutting aspects related to nanomedicine

In this framework, the ICTS NANBIOSIS has been presented by the Scientific Director of CIBER-BBN, Ramón Martínez Máñez, to the European Nanomedicine community.

EUROPEAN TECHNICAL PLATFORM OF NANOMEDICINE

The European Technology Platforms are a key element in the European field of innovation, associations born with the mission of sharing knowledge, mobilizing the actors involved and developing sector strategies, all based on the social challenges established by the European Commission and with the ultimate goal of its translation to the market.

The European Nanomedicine Technology Platform (ETPN) was created in 2005 by the European Commission and a group of experts from academia and industry who have since contributed to the publication of various strategic documents identifying the needs and the roadmaps for research in Nanomedicine in Europe. Its main objectives are to establish a clear strategic vision of the sector, to reduce the fragmentation of nanomedical research, to mobilize public and private investment, to identify priority areas, to promote innovation in nanobiotechnologies for medical use and to strengthen Europe’s competitiveness in this sector scientific and industrial level

Currently, the ETPN has more than 120 members from 25 countries, representing all actors involved in nanomedicine, such as academic institutions, research centers, small and medium enterprises, industry, public agencies, representatives of the platforms the European Commission itself, among others.

• Read More

NANBIOSIS: collaborative research opportunities for groups of CIBER consortia

Last week, Jesús Izco, coordinator of NANBIOSIS, presented to CIBER groups the capabilities of NANBIOSIS and the opportunities for collaboration with the ICTS. From these meetings emerged diverse expressions of interest on the part of the attending researchers.

On June 30, Jesús Izco was invited to present NANBIOSIS in the Annual Scientific Conference of CIBERES. He explained several investigations that are currently being developed in NANBIOSIS and can be applied in the diagnosis and therapy of respiratory diseases, such as the development of physical devices and tests that allow the detection of biomarkers, new protein carriers in the format of nanoparticles capable of recognizing cell receptors and being endocytosed in order to deliver drugs or toxins in target tissues, or non-viral vectors based on niosomes for pulmonary gene therapy (eg cystic fibrosis) by inhalation.

Also, on June 28, Dr. Izco participated in a meeting at the Carlos III Health Institute (Madrid) with the working group on lung cancer of CIBERONC about respiratory tract tumors. Jesús Izco presented both examples of the projects currently under development in the NANBIOSIS units with application to the detection and monitoring of lung cancer, such as PreDICT, and examples of results already published in this scientific area.

• Read More